Rapport Therapeutics (RAPP) Gains from Investment Securities (2023 - 2025)
Rapport Therapeutics (RAPP) has 3 years of Gains from Investment Securities data on record, last reported at $6.3 million in Q3 2025.
- On a quarterly basis, Gains from Investment Securities changed N/A to $6.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.3 million, a N/A change, with the full-year FY2025 number at $6.3 million, up 6483.75% from a year prior.
- Gains from Investment Securities reached $6.3 million in Q3 2025 per RAPP's latest filing, up from $6.1 million in the prior quarter.
- Over the last five years, Gains from Investment Securities for RAPP hit a ceiling of $6.3 million in Q3 2025 and a floor of $95500.0 in Q4 2024.
- A 3-year average of $3.1 million and a median of $1.6 million in 2025 define the central range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 93.06% in 2024 and fell as far as 93.06% in 2024.
- Tracing RAPP's Gains from Investment Securities over 3 years: stood at $1.4 million in 2023, then plummeted by 93.06% to $95500.0 in 2024, then skyrocketed by 6493.37% to $6.3 million in 2025.
- Business Quant data shows Gains from Investment Securities for RAPP at $6.3 million in Q3 2025, $6.1 million in Q2 2025, and $1.6 million in Q1 2025.